Metastatic Castrate Refractory Prostate Cancer (mCRPC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Advanced forms of the disease that do not respond to initial treatments, such as surgery and hormone therapy, and have begun to spread outside of the prostate are known as metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer incidence and death vary greatly over the world, and in addition to individual risk factors, a large portion of this variation has been related to variations in asymptomatic disease screening patterns. Despite castration, the majority of men with PCa will eventually experience disease progression. Only a slight survival advantage for patients continuing on LHRH analogues during second- and third-line therapies has been demonstrated in two trials. Since the advent of systemic therapies that enhance QoL and survival, the management of metastatic castration-resistant prostate cancer has undergone significant change.

Description

Advanced forms of the disease that do not respond to initial treatments, such as surgery and hormone therapy, and have begun to spread outside of the prostate are known as metastatic castration-resistant prostate cancer (mCRPC) and its precursor, metastatic hormone sensitive prostate cancer (mHSPC). When compared to mHSPC, the type mCRPC differs in that even after the disease has spread to other parts of the body, it still responds to the standard hormone therapy known as androgen deprivation therapy (ADT). In particular, the castration-resistant form mCRPC is extremely dangerous and has a very poor prognosis. Prostate cancer (PCa) is the second most common malignancy in men, with 15% of men in the world receiving a diagnosis at some point in their lives. With a diagnosis, 80% of patients will have a localized form, and their chance of surviving for five years is greater than 100%. Of the remaining 20%, only 26-30% will live for 5 years, and all of them will have an advanced or metastatic form of the disease. Androgen deprivation therapy (ADT) has been the mainstay of PCa early care for decades because PCa cancer cells are sensitive to the manipulation of testosterone and its metabolites. The hallmark of castration-resistant prostate cancer (CRPC) is disease progression despite castrate testosterone levels. It could show up as a persistent increase in serum PSA levels, the progression of an existing condition, or the emergence of new metastases.

Metastatic Castrate Refractory Prostate Cancer (mCRPC) (Epidemiology)

Prostate cancer incidence and death vary greatly over the world, and in addition to individual risk factors, a large portion of this variation has been related to variations in asymptomatic disease screening patterns. For instance, the age-standardized incidence rate in a low-income region like Western Africa is only 31.9 per 100000, yet the associated mortality is significant at 18.6 per 100000. In contrast, the age-standardized incidence is substantially higher in a high-income region like North America (73.7 per 100000), but the related mortality is just 7.7 per 100000, which is rather low. High-income nations often have high detection rates for localised disease, possibly as a result of PSA testing identifying earlier disease with the associated mortality reduction from treating the lower-risk disease as well as availability to more advanced diagnostic and therapeutic options.

Metastatic Castrate Refractory Prostate Cancer (mCRPC) -Current Market Size & Forecast Trends

The market for metastatic castrate-resistant prostate cancer (mCRPC) is projected to grow significantly, with estimates indicating an increase from approximately USD 7.3 billion in 2024 to about USD 12.8 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.3% during this period. This growth is driven by the rising prevalence of prostate cancer, particularly among aging populations, and advancements in treatment options, including next-generation hormonal therapies, chemotherapy, and immunotherapies. Additionally, the market is expected to benefit from increasing awareness of mCRPC and the importance of early diagnosis and treatment. Key players in the market include major pharmaceutical companies known for their innovative therapies, which are essential for addressing this aggressive form of prostate cancer. Overall, the mCRPC market is well-positioned for substantial expansion through 2035, supported by ongoing research and development efforts aimed at improving patient outcomes.

Despite castration, the majority of men with PCa will eventually experience disease progression. Only a slight survival advantage for patients continuing on LHRH analogues during second- and third-line therapies has been demonstrated in two trials. Since the advent of systemic therapies that enhance QoL and survival, the management of metastatic castration-resistant prostate cancer has undergone significant change. In the metastatic castration-sensitive state, several clinical trials reported improved outcomes with the intensification of androgen deprivation therapy by the addition of docetaxel chemotherapy or novel hormonal agents (abiraterone, enzalutamide, or apalutamide). Relugolix was recently approved as the first oral gonadotropin-releasing hormone receptor antagonist drug with superior cardiovascular side-effect profile and serum testosterone suppression compared to gonadotropin-releasing hormone agonist leuprolide. Olaparib and rucaparib, poly-ADP ribose polymerase inhibitors that have been approved by the Food and Drug Administration, have shown a significant clinical benefit for patients who have harmful mutations in genes involved in homologous recombination repair. Prostate-specific membrane antigen-617 lutetium-177 has recently been shown to improve overall survival in men with metastatic castration-resistant prostate cancer that has reached an advanced stage and is prostate-specific membrane antigen positive.

Report Highlights

Metastatic Castrate Refractory Prostate Cancer (mCRPC) - Current Market Trends

Metastatic Castrate Refractory Prostate Cancer (mCRPC) - Current & Forecasted Cases across the G8 Countries

Metastatic Castrate Refractory Prostate Cancer (mCRPC) - Market Opportunities and Sales Potential for Agents

Metastatic Castrate Refractory Prostate Cancer (mCRPC) - Patient-based Market Forecast to 2035

Metastatic Castrate Refractory Prostate Cancer (mCRPC) - Untapped Business Opportunities

Metastatic Castrate Refractory Prostate Cancer (mCRPC) - Product Positioning Vis-a-vis Competitors' Products

Metastatic Castrate Refractory Prostate Cancer (mCRPC) - KOLs Insight